ENGN
enGene Holdings Inc

1,173
Mkt Cap
$482.99M
Volume
193,065.00
52W High
$12.25
52W Low
$2.65
PE Ratio
-3.20
ENGN Fundamentals
Price
$7.21
Prev Close
$7.22
Open
$7.19
50D MA
$9.22
Beta
0.42
Avg. Volume
243,659.93
EPS (Annual)
-$2.29
P/B
1.72
Rev/Employee
$0.00
$206.55
Loading...
Loading...
News
all
press releases
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care PR Newswire VANCOUVER, BC, March 19, 2026...
PR Newswire·4d ago
News Placeholder
More News
News Placeholder
Short Interest in enGene Holdings Inc. (NASDAQ:ENGN) Decreases By 17.7%
enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) was the recipient of a large decrease in short interest during the month of February. As of February 27th, there was short interest totaling...
MarketBeat·6d ago
News Placeholder
enGene Shares Detalimogene NMIBC Trial Changes, FDA Endpoint Shift, and 2027 Approval Path at Conference
Executives from enGene (NASDAQ:ENGN) provided an update on the company's detalimogene program in non-muscle invasive bladder cancer (NMIBC), discussing recent protocol changes, regulatory...
MarketBeat·7d ago
News Placeholder
enGene Highlights 2026 Data Catalysts, BLA Plans for Bladder Cancer Gene Therapy at Barclays Conference
enGene (NASDAQ:ENGN) CEO Ron Cooper said the company's focus is advancing its DDX platform, a proprietary non-viral gene therapy technology, with its lead program detalimogene being developed for...
MarketBeat·7d ago
News Placeholder
enGene CEO Pitches Detalimogene as Community-Friendly NMIBC Option, Teases Q2 LEGEND Data Update
enGene (NASDAQ:ENGN) Chief Executive Officer Ron Cooper used a presentation at the Citizens Life Sciences Conference to outline the company's approach to non-muscle invasive bladder cancer (NMIBC...
MarketBeat·7d ago
News Placeholder
Braidwell LP Invests $15.48 Million in enGene Holdings Inc. $ENGN
Braidwell LP purchased a new stake in enGene Holdings Inc. (NASDAQ:ENGN - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 2,266,319...
MarketBeat·8d ago
News Placeholder
enGene (NASDAQ:ENGN) Upgraded to "Hold" at Wall Street Zen
Wall Street Zen raised enGene from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·9d ago
News Placeholder
enGene (NASDAQ:ENGN) Sees Unusually-High Trading Volume - Should You Buy?
enGene (NASDAQ:ENGN) Sees Large Volume Increase - Here's What Happened...
MarketBeat·10d ago
News Placeholder
HC Wainwright Has Optimistic Outlook of enGene Q2 Earnings
enGene Holdings Inc. (NASDAQ:ENGN - Free Report) - Stock analysts at HC Wainwright upped their Q2 2026 earnings per share (EPS) estimates for enGene in a research note issued on Monday, March 9th. HC...
MarketBeat·11d ago
News Placeholder
enGene (NASDAQ:ENGN) Price Target Lowered to $30.00 at Oppenheimer
Oppenheimer cut their target price on shares of enGene from $33.00 to $30.00 and set an "outperform" rating on the stock in a report on Wednesday...
MarketBeat·11d ago
<
1
2
...
>

Latest ENGN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.